Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route of Administration, By Application (Deep Vein Thrombosis (DVT)), Pulmonary Embolism), By Region, And Segm
Description
Anticoagulants Market Summary
The global anticoagulants market size was estimated at USD 37.35 billion in 2025 and is projected to reach USD 55.72 billion by 2033, growing at a CAGR of 5.26% from 2026 to 2033. The rising prevalence of cardiovascular diseases, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Atrial Fibrillation (AF), is expected to drive demand for anticoagulants.
In recent years, a rise in venous thromboembolism (VTE) has been reported across various regions. According to the U.S. Centers for Disease Control and Prevention (CDC), in the U.S., up to 900,000 individuals are affected by it each year. CDC also states that nearly 60,000-100,000 fatalities are caused by venous thromboembolism (VTE) every year. Health professionals prefer using anticoagulants to prevent thromboembolic events and complications such as strokes. These aspects are likely to generate significant growth in demand in the anticoagulants industry.
A sedentary lifestyle, increasing urbanization, changing dietary preferences, and a lack of physical activity have contributed to the growing number of individuals experiencing cardiovascular diseases. VTE is also linked with multiple other conditions, including cancer, complicated surgeries, pregnancy, and others. According to the CDC, VTE is one of the leading causes of preventable hospital deaths in the U.S. Such aspects are expected to result in continuous growth in the adoption of anticoagulants.
Recent advancements in healthcare technology related to anticoagulants are anticipated to assist the market in growing. For instance, in February 2024, Roche (F. Hoffmann-La Roche Ltd.) launched novel Factor Xa inhibitor coagulation tests designed to facilitate clinical decisions regarding the prescription of direct oral anticoagulants, primarily for stroke prevention. Furthermore, the increasing incidence of stroke is projected to propel the market growth during the forecast period. Blood thinners are used for stroke prevention in individuals at risk due to various conditions, such as atrial fibrillation, certain heart valve disorders, and previous strokes. As per the CDC, over 795,000 individuals in the U.S. experience stroke every year, out of which approximately 610,000 are first-time or new strokes.
Global Anticoagulants Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the anticoagulants market report based on drug category, route of administration, application, and region:
The global anticoagulants market size was estimated at USD 37.35 billion in 2025 and is projected to reach USD 55.72 billion by 2033, growing at a CAGR of 5.26% from 2026 to 2033. The rising prevalence of cardiovascular diseases, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Atrial Fibrillation (AF), is expected to drive demand for anticoagulants.
In recent years, a rise in venous thromboembolism (VTE) has been reported across various regions. According to the U.S. Centers for Disease Control and Prevention (CDC), in the U.S., up to 900,000 individuals are affected by it each year. CDC also states that nearly 60,000-100,000 fatalities are caused by venous thromboembolism (VTE) every year. Health professionals prefer using anticoagulants to prevent thromboembolic events and complications such as strokes. These aspects are likely to generate significant growth in demand in the anticoagulants industry.
A sedentary lifestyle, increasing urbanization, changing dietary preferences, and a lack of physical activity have contributed to the growing number of individuals experiencing cardiovascular diseases. VTE is also linked with multiple other conditions, including cancer, complicated surgeries, pregnancy, and others. According to the CDC, VTE is one of the leading causes of preventable hospital deaths in the U.S. Such aspects are expected to result in continuous growth in the adoption of anticoagulants.
Recent advancements in healthcare technology related to anticoagulants are anticipated to assist the market in growing. For instance, in February 2024, Roche (F. Hoffmann-La Roche Ltd.) launched novel Factor Xa inhibitor coagulation tests designed to facilitate clinical decisions regarding the prescription of direct oral anticoagulants, primarily for stroke prevention. Furthermore, the increasing incidence of stroke is projected to propel the market growth during the forecast period. Blood thinners are used for stroke prevention in individuals at risk due to various conditions, such as atrial fibrillation, certain heart valve disorders, and previous strokes. As per the CDC, over 795,000 individuals in the U.S. experience stroke every year, out of which approximately 610,000 are first-time or new strokes.
Global Anticoagulants Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the anticoagulants market report based on drug category, route of administration, application, and region:
- Drug Category Outlook (Revenue, USD Million, 2021 - 2033)
- Novel Oral Anticoagulants (NOACs)
- Eliquis
- Xarelto
- Savaysa & lixiana
- Pradaxa
- Vitamin K Antagonist
- Direct Thrombin Inhibitors
- Heparin
- Type
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
- Unfractionated Heparin
- Source
- Porcine
- Bovine
- Others
- Others
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral Anticoagulants
- Injectable Anticoagulants
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Other Applications
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
